Why is the Rhythm Biosciences (ASX:RHY) share price up 11% on Monday?

The med-tech's shares are finding their own rhythm today.

| More on:
A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price is lifting in early trade today as the medical technology company released an investor presentation.

At the time of writing, Rhythm Biosciences shares are changing hands at $1.50 each, signifying an 11% gain on the day.

Here are the details out of Rhythm's camp today.

What was announced?

Rhythm gave a presentation regarding its "simple, low-cost blood test for the early detection of colorectal cancer", known as ColoSTAT.

The company explains that ColoSTAT is a disruptive and transformative technology that is significantly cheaper and easier to administer than competing tests.

In fact, the assay format of ColoSTAT is designed to "integrate with existing pathology lab infrastructure" using a combination of a test kit and an algorithm to analyse the results.

It appears the company expects tremendous growth for the industry, forecasting a US$38 billion total addressable "screening value" and a total addressable market of 771 million people.

It forecasts it has the potential to reach 1 billion people if the screening age is lowered to 45 years old. This is based on what the US Preventative Services Task Force is currently advocating.

If Rhythm wants to successfully commercialise the product, its tests "must demonstrate both sensitivity greater than or equal to 74% and specificity greater than or equal to 90%".

According to the company, it would meet these requirements in the US now "based on the study 6 performance of 84% sensitivity and 95% specificity".

Aside from this, the company has also filed intellectual property (IP) patents in all its major target markets.

The patent, which expires in 2031, has been granted in a number of jurisdictions with just India pending.

Rhythm is targeting initial revenues for the product in late 2022 and it has already commenced its "platform technology pipeline for additional cancer detection tests".

What's next for Rhythm Biosciences?

The presentation also contained several "future value inflection points" that may weigh in on the Rhythm Biosciences share price.

It stated that it expects CE Mark submission and approval in Europe to be completed in late 2021. At the same time, it has progressed regulatory post-clinical trial recruitment in Australia for its "Study 7".

As well, it will continue progressing its IP approvals in different markets while building out its sales and distribution channels for ColoSTAT.

Rhythm Biosciences share price snapshot

The Rhythm Biosciences share price has been an outsized winner this year to date posting a return of 72% since January 1. Indeed, it's up almost 14% over the last month alone.

On a 12 month basis, the company's shares have rallied an incredible 618%.

These results have far outpaced the S&P/ASX 200 Index (ASX: XJO)'s climb of around 21% over the same time.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Appen, Mayne Pharma, Playside, and PYC shares are storming higher

These shares are ending the week on a positive note. But why?

Read more »

chip and tech stocks represented by two computer chips side by side
Technology Shares

This little ASX AI stock is soaring 10% today. Here's why

Investors are piling into the ASX AI stock on Friday. But why?

Read more »

A man in a business suit wearing boxing gloves slumps in the corner of a boxing ring representing the beaten-up Zip share price in recent times
Industrials Shares

Beaten-up ASX 200 stock surges 12% on buyout rumour

This ASX 200 building materials stock has been struggling throughout FY24.

Read more »

A person wears a roaring lion mask.
Share Gainers

Guess how much a $3,000 investment in Liontown shares ballooned to in just one month

After a lengthy slide, Liontown shares came roaring back this past month.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Australian Ethical, Cromwell Property, Smartpay, and Xero shares are surging

These ASX shares are having a very strong session. But why?

Read more »

A young woman makes an online travel booking as she sits on some steps with her suitcase next to her.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares snatched defeat from the jaws of victory today.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Share Gainers

Why Droneshield, TechnologyOne, Telix, and Webjet shares are rising today

These shares are having a great session. But why?

Read more »

flying asx share price represented by man flying remote control drone
Share Gainers

Up 246% in a year, here's why the Droneshield share price is racing higher again today

ASX investors are sending the Droneshield share price soaring today. But why?

Read more »